Investigational Drug Information for DWP16001

What is the development status for investigational drug DWP16001?

DWP16001 is an investigational drug.

There have been 25 clinical trials for DWP16001. The most recent clinical trial was a Phase 1 trial, which was initiated on September 23^rd 2024.

The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Glucose Metabolism Disorders. The leading clinical trial sponsors are Daewoong Pharmaceutical Co. LTD. and [disabled in preview].

There are forty-one US patents protecting this investigational drug and one hundred and thirty-seven international patents.

Summary for DWP16001

US Patents	41
International Patents	137
US Patent Applications	98
WIPO Patent Applications	45
Japanese Patent Applications	12
Clinical Trial Progress	Phase 1 (2024-09-23)
Vendors	30

Recent Clinical Trials for DWP16001

Title	Sponsor	Phase
Drug-Drug Interaction Study to Evaluate the Effect of DWC202511 or DWC202512 With DWP16001 in Healthy Adults	Daewoong Pharmaceutical Co. LTD.	PHASE1
Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy Adults	Daewoong Pharmaceutical Co. LTD.	PHASE1
Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients	Daewoong Pharmaceutical Co. LTD.	PHASE3

See all DWP16001 clinical trials

Clinical Trial Summary for DWP16001

Top disease conditions for DWP16001

Top clinical trial sponsors for DWP16001

See all DWP16001 clinical trials

US Patents for DWP16001

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
DWP16001		Process for making tetracyclic heterocycle compounds	MSD R&D China Co Ltd , Merck Sharp and Dohme UK Ltd , Merck Sharp and Dohme LLC
DWP16001		Heterocycles useful as IDO and TDO inhibitors	Hangzhou Innogate Pharma Co Ltd
DWP16001		Method for producing diphenylmethane derivative	Daewoong Pharmaceutical Co Ltd , GC Biopharma Corp
DWP16001		Versatile ligand for palladium-catalyzed meta-C—H functionalizations of aromatic substrates	Scripps Research Institute
DWP16001		Mammalian and bacterial nitric oxide synthase inhibitors	Northwestern University

International Patents for DWP16001

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
DWP16001	Australia	AU2020404984	2039-12-17
DWP16001	Brazil	BR112022012075	2039-12-17
DWP16001	Canada	CA3161516	2039-12-17
DWP16001	China	CN113272013	2039-12-17
DWP16001	China	CN116173014	2039-12-17

Last updated: April 23, 2026

DWP16001 Development Update and Market Projection

What is DWP16001 and what is its development stage?

No complete, citable public development dossier for the drug candidate “DWP16001” is available in the materials provided in this chat. Without validated identifiers (INN/USAN, company, MoA target class, lead indication, clinical trial registry entries, or sponsor documents), a development status update cannot be produced without risking incorrect attribution.

Which indications, mechanisms, and trial programs define DWP16001’s pipeline value?

A market projection requires at minimum: (1) target indication, (2) mechanism of action (MoA) and comparators, (3) clinical phase and endpoints, and (4) expected label scope (patient population and use conditions). None of these data fields are present here for DWP16001.

What market model can be used for DWP16001?

A standard, decision-grade projection model for a development-stage drug uses:

• Epidemiology/TAM: diagnosed prevalent or incident cases for the intended line of therapy
• Treatment uptake: share eligible for biologic or oral therapy, and expected adoption curves
• Pricing: ex-manufacturer or WAC-style proxy, with discounting assumptions
• Utilization: dosing regimen and persistence (for chronic therapies) or cycles (for oncology)
• Commercial constraints: payer rules, step edits, administration setting
• Competition: current standard-of-care and expected next entrants

No indication, label hypothesis, geography, or competitor set exists for DWP16001 in the provided context, so a market model cannot be anchored.

How should investors and R&D teams frame “market projection” for an unanchored candidate?

For a candidate with undefined public parameters, only two projection classes are feasible:

• Relative scenario bands based on mechanism class and known comparator economics
• Trial-based milestone gating that converts probability of success into expected value

Both require at least the indication/MoA and a phase and trial dataset. Those inputs are missing for DWP16001 here.

---

Key Takeaways

• A development update and market projection for DWP16001 cannot be produced from the information available in this chat without risking incorrect identification of the candidate and its clinical program.
• A credible market projection requires the candidate’s indication, mechanism, phase, label scope, geography, pricing anchor, and comparator set; none are provided.

FAQs

1. What does “DWP16001” refer to in public filings?
   Not determinable from the information provided in this chat.

2. What clinical phase is DWP16001 in?
   Not determinable from the information provided in this chat.

3. What indication is DWP16001 targeting?
   Not determinable from the information provided in this chat.

4. What is the expected pricing and market size approach for DWP16001?
   It requires indication, label scope, and comparators; those inputs are not present here.

5. Can a TAM/SAM/SOM projection be estimated without trial and indication data?
   Not to decision-grade standards; projection inputs are missing.

References

[1] No sources cited because no verifiable public data for DWP16001 is present in the provided context.